Genetic resilience to chronic obstructive pulmonary disease is a clinically distinct subtype in individuals with cigarette smoke exposure
Genetic resilience to COPD represents a unique subtype of smokers that is distinct from clinical resilience and has important disease-related differences from genetic risk-matched individuals with COPD. Future studies are needed to identify the underlying biological contributors to the multiple types of resilience in COPD.
Authors
- Russell Paul Bowler (ORCID: https://orcid.org/0000-0003-4651-363X)
- Michael H. Cho (ORCID: https://orcid.org/0000-0002-4907-1657)
- Auyon Ghosh (ORCID: https://orcid.org/0000-0003-0334-4039)
- Stephen J. Glatt (ORCID: https://orcid.org/0000-0002-0360-7567)
- Craig P. Hersh (ORCID: https://orcid.org/0000-0002-1342-4334)
- Santosh Kumar Panda (ORCID: https://orcid.org/0000-0003-0421-8747)
- Matthew Moll (ORCID: https://orcid.org/0000-0002-0683-0975)
- Liam P. Coyne (ORCID: https://orcid.org/0000-0002-4480-126X)
- Jonathan Hess (ORCID: https://orcid.org/0000-0001-8406-632X)
- K.-Y. Chang (ORCID: https://orcid.org/0009-0005-1041-4797)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Johns Hopkins University (US)
- SUNY Upstate Medical University (US)
- Johns Hopkins Medicine (US)
- Cleveland Clinic Lerner College of Medicine (US)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1186/s12931-025-03380-w
- Primary Topic
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- COPD Foundation
- Sunovion
- National Institutes of Health
- Genentech
- National Heart, Lung, and Blood Institute